e-Therapeutics Plc (ETX) - Financial and Strategic SWOT Analysis Review

July 2021 | 55 pages | ID: E8E04A29FA3EN
GlobalData

Abstracts

e-Therapeutics Plc (ETX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – Analyst’s summarization of the company’s business strategy.
• SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
• Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
• Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

e-Therapeutics Plc (e-Therapeutics) is a drug discovery and development company with focus on discovering novel therapeutic approaches and mechanisms for the treatment of various diseases such as cancer, diabetes, and neurodegenerative disease. It carries out its work by integrating proprietary databases and computational tools that use network analysis, machine learning, Al, data mining, and optimization. The company harnesses its two proprietary, productive, and unique technology platforms, Network-Driven Drug Discovery (NDD) and Genome Associated Network Interactions (GAINs), for target validation and novel discovery. e-Therapeutics has research partnership with Novo Nordisk for developing therapeutics for type 2 diabetes. e-Therapeutics is headquartered in Long Hanborough, England, the UK.

e-Therapeutics Plc Key Recent Developments

Jun 02,2021: e-Therapeutics: Senior management appointment and options grant
May 21,2021: e-therapeutic Notice of Annual General Meeting and Posting of Annual Report and Accounts
May 21,2021: e-therapeutics Notice of Annual General Meeting and Posting of Annual Report and Accounts
May 13,2021: e-Therapeutics announces Final Results for the Year Ended 31 January 2021
May 13,2021: e-therapeutics: Final results for the year ended 31 January 2021

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

e-Therapeutics Plc - Key Facts
e-Therapeutics Plc - Key Employees
e-Therapeutics Plc - Key Employee Biographies
e-Therapeutics Plc - Major Products and Services
e-Therapeutics Plc - History
e-Therapeutics Plc - Company Statement
e-Therapeutics Plc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
e-Therapeutics Plc - Business Description
e-Therapeutics Plc - Corporate Strategy
e-Therapeutics Plc - SWOT Analysis
SWOT Analysis - Overview
e-Therapeutics Plc - Strengths
e-Therapeutics Plc - Weaknesses
e-Therapeutics Plc - Opportunities
e-Therapeutics Plc - Threats
e-Therapeutics Plc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

e-Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
e-Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
e-Therapeutics Plc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Jun 02, 2021: e-Therapeutics: Senior management appointment and options grant
May 21, 2021: e-therapeutic Notice of Annual General Meeting and Posting of Annual Report and Accounts
May 21, 2021: e-therapeutics Notice of Annual General Meeting and Posting of Annual Report and Accounts
May 13, 2021: e-Therapeutics announces Final Results for the Year Ended 31 January 2021
May 13, 2021: e-therapeutics: Final results for the year ended 31 January 2021
May 13, 2021: e-therapeutics announce Final Results for the Year Ended 31 January 2021
Apr 23, 2021: ETX to receive two payments from Galapagos
Feb 01, 2021: e-therapeutics: RNA therapeutics platform
Oct 12, 2020: e-therapeutics appoints Ali Mortazavias Chief Executive Officer
Oct 12, 2020: e-therapeutics: Interim Financial Results for the six months ended 31 July 2020

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

e-Therapeutics Plc, Key Facts
e-Therapeutics Plc, Key Employees
e-Therapeutics Plc, Key Employee Biographies
e-Therapeutics Plc, Major Products and Services
e-Therapeutics Plc, History
e-Therapeutics Plc, Other Locations
e-Therapeutics Plc, Subsidiaries
e-Therapeutics Plc, Key Competitors
e-Therapeutics Plc, Ratios based on current share price
e-Therapeutics Plc, Annual Ratios
e-Therapeutics Plc, Annual Ratios (Cont...1)
e-Therapeutics Plc, Interim Ratios
e-Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
e-Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
e-Therapeutics Plc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

e-Therapeutics Plc, Performance Chart (2017 - 2021)
e-Therapeutics Plc, Ratio Charts
e-Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
e-Therapeutics Plc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021